

A stable, safe and efficacious *Toxoplasma* vaccine

The Problem


- *Toxoplasma* infection is a leading cause of ovine abortion, resulting in >\$70 million of annual losses in Australia alone
- The existing ovine vaccine (Toxovax, MSD) has a very short shelf-life (7 days), cannot be used in Australia, and is not genetically characterised

The Solution

- A genetically-defined, attenuated parasite strain which protects sheep and other mammals from *Toxoplasma* infection
- A stable vaccine formulation with sufficient shelf life to enable ease of manufacture and global distribution

Our Program

- Spearheaded by A/Prof Chris Tonkin, leader in the field, with recent publications in *Elife* and *Cell Host & Microbe*
- Our strain has a novel differentiation method which is likely to *increase stability*. We are conducting PoC experiments to determine vaccine shelf life.
- Our genetically-attenuated vaccine strain is protected by patent



Our Team

A/Prof Chris Tonkins, Infectious Diseases and Immune Defence

Victoria Jameson, PhD, Business Development Lead
jameson.v@wehi.edu.au